ArticleJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi2022
Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients.
Article in Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The association of human leucocyte antigen (HLA) alleles with COVID-19 severity: A systematic review and meta-analysis.Reviews in medical virology · 2023Pooled it
- Investigation ofInternational journal of molecular sciences · 2025Article
- Influence of HLA Class I and II Polymorphisms on COVID-19 Severity in a South Brazilian Population.International journal of molecular sciences · 2025Article
- Association between HLA genetics and SARS-CoV-2 infection in a large real-world cohort.Genes and immunity · 2025Article
- HLA Polymorphisms and COVID-19 Susceptibility and Severity: Insights From an Iranian Patients Cohort.Journal of cellular and molecular medicine · 2025Article
- The HLA-B -21 M/T dimorphism associates with disease severity in COVID-19.Genes and immunity · 2025Article
- Association of Human Leukocyte Antigen Alleles with COVID-19 Severity and Mortality in a Spanish Population.Medicina (Kaunas, Lithuania) · 2024Article
- Narrative Review Explaining the Role ofInfectious disease reports · 2024Review
- Evaluation the frequencies of HLA alleles in moderate and severe COVID-19 patients in Iran: A molecular HLA typing study.Heliyon · 2024Article
- HLA-DQ2/8 and COVID-19 in Celiac Disease: Boon or Bane.Microorganisms · 2023Article
- HLA-Bw4 in association with KIR3DL1 favors natural killer cell-mediated protection against severe COVID-19.Emerging microbes & infections · 2023Article
- Rare peptide anchors of HLA class I alleles contribute to the COVID-19 disease severity and T cell memory.Biosafety and health · 2023Article
- Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population.Archives of Iranian medicine · 2023Article
- HLA Variation and SARS-CoV-2 Specific Antibody Response.Viruses · 2023Review
- HLA alleles associated with COVID-19 susceptibility and severity in different populations: a systematic review.The Egyptian journal of medical human genetics · 2023Review
- Association of Alleles of Human Leukocyte Antigen Class II Genes and Severity of COVID-19 in Patients of the 'Red Zone' of the Endocrinology Research Center, Moscow, Russia.Diseases (Basel, Switzerland) · 2022Article
- Shared 6mer Peptides of Human and Omicron (21K and 21L) at SARS-CoV-2 Mutation Sites.Antibodies (Basel, Switzerland) · 2022Article
- Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients.International journal of molecular sciences · 2022Article
- Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19.International journal of molecular sciences · 2022Article
- Susceptibility and Severity of COVID-19 Are Both Associated With Lower Overall Viral-Peptide Binding Repertoire of HLA Class I Molecules, Especially in Younger People.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman leukocyte antigen (HLA) plays an important role in immune responses to infections, especially in the development of acquired immunity. Given the high degree of polymorphisms that HLA molecules present, some will be more or less effective in controlling SARS-CoV-2 infection. We wanted to analyze whether certain polymorphisms may be involved in the protection or susceptibility to COVID-19.
methodsWe studied the polymorphisms in HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and HLA-DQB1) molecules in 450 patients who required hospitalization for COVID-19, creating one of the largest HLA-typed patient cohort to date.
resultsOur results show that there is no relationship between HLA polymorphisms or haplotypes and susceptibility or protection to COVID-19.
conclusionOur results may contribute to resolve the contradictory data on the role of HLA polymorphisms in COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.